These guys are certainly efficient, the pace of advancement compared some bigger BioTech coys is a pleasure to see. Tick the Ethics box and lets move on to the next phase....
The market has not caught on yet, at AU $28m market cap with $8m cash we are nicely set up for re-rating.
Interesting to see valuations of their Peers on NASDAQ:
Novan US$ 81m
Zynerba US$ 200m
Cassiopea US$ 340m
Demira US$ 1.2 billion
Must say, a move to NASDAQ could definitely unleash the beast...although a TO or liquidity event could take place in the next 12 or so months.
Excited to be in this one.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $323.5M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.0¢ | $3.657M | 21.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 180978 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 529694 | 12 |
View Market Depth
| Last trade - 16.18pm 28/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |